Experts believe a wider spat with Europe would be much more damaging than the current tit-for-tat with China.Traderead more
After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Markets pay particular attention to Italy's spending, given its public debt pile. This stands at above 130% of its growth rate, one of the highest in the world.Politicsread more
Office phones, printers, building control systems and more — these may not sound like computers but they can all be hacked according to cybersecurity pros.Technologyread more
Software stocks are the place to be in tech as the sector mounts a recovery from its recent pullback, some analysts say.Trading Nationread more
Flight bookings to Hong Kong have fallen 10%, hit by the unrest in the city, said Alan Joyce, the chief executive of Australian carrier Qantas Airways.Airlinesread more
South Korea will scrap an intelligence-sharing pact with Japan amid an intensifying dispute over history and trade, South Korea's presidential office said on Thursday.Asia Politicsread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
Toyota's revolutionary approach to manufacturing turned it from a tiny Japanese automotive latecomer into one of the biggest car companies in the world. But its designs have...Autosread more
These in-demand skills can command top pay packets, says Feon Ang of professional networking site LinkedIn.Get Aheadread more
Shares of Cambridge, Mass.-based biopharmaceutical company Sage Therapeutics are popping after the company announced positive results in trials for a drug that may someday be available to treat those with postpartum depression.
The company is up more than 40 percent to $96.75 this week following two Phase 3 trials evaluating brexanolone. The drug, formerly known as SAGE-547, achieved a significant reduction in depression symptoms after only 60 hours, a rapid reduction in treatment time compared to the options currently available to those suffering from the condition.
"We are on the cusp of a major discovery," CEO Jeff Jonas said Friday on CNBC's Power Lunch.
Analysts from Canaccord Genuity said the probability of FDA approval following the trials increased to about 80 percent.
Postpartum depression occurs in nearly 15 percent of births, according to the National Institute of Mental Health. It can include feelings of sadness and anxiety that can limit the ability of those suffering from the condition to take care of themselves or their families.
Current treatment for the condition includes counseling and medication, including anti-depressants. Anti-depressants can take weeks to be effective.
Brexanolone is administered intravenously. The company is also working on an oral treatment called SAGE-217.
The analysts at Canaccord upped their price target for the company to $140.